Expanded Abilities at Your Disposal

Expanded Abilities at Your Disposal

The surge in precision medicine, a personalized approach to healthcare, can be attributed to a host of factors that have propelled its growth in recent years.

Artificial intelligence (AI) and big data analysis play a pivotal role. As per reports by NIH, these techniques are employed to analyze vast health databases, which in turn contribute to the development of biomarkers for diagnosing, predicting, and treating specific disease subtypes [1]. This streamlined the entire process involving medical data collection, processing, and interpretation.

Regulatory agencies have also taken notable steps to support precision medicine. In 2018, FDA approvals for precision medicine increased to 40%, doubling from the previous percentage between 2013 and 2018 [1]. Similarly, in 2021, the FDA approved 17 new personalized medicines, amounting to more than a quarter of the drugs it approved over the past seven years [2]. Both the EMA and FDA recognized the need for flexible regulations and new guidelines to facilitate the development and application of precision medicine.

Consumer awareness is also on the rise, as a study by PMC found that even those initially unfamiliar with personalized medicine demonstrated a positive response upon learning about its potential benefits [3]. This sentiment has opened up opportunities for numerous organizations to innovate in the field. Interestingly, universities are taking the lead in this endeavor [3].

One illustrative example is the collaboration between the University of California and AstraZeneca. Utilizing pharmacokinetic modeling, they aim to predict the efficacy of IL23 antagonists (such as the anti-IL23 monoclonal antibody) for treating Crohn's disease. To protect their innovation, they have even filed a patent [4].

Moreover, QU Biologics, a Canadian Biotech startup, has teamed up with Ottawa Hospital Research Institute to develop mycobacterial immunotherapy for cancer treatment. Their patent outlines the use of surgical treatment in combination with neoadjuvant or adjuvant preparations, containing innate immunogens like microbial components, to enhance the immune response [4].

South Korean startup KBlueBio and Chonnam National University also collaborated to create innovative precision medicine solutions. Their patent is based on designing an RNA sequencing panel & the corresponding analysis algorithm [4].

It is evident that universities worldwide are actively exploring the field of Precision medicine.

OncXerna, a US-based startup, has developed a platform that utilizes proprietary RNA-based gene expression data and machine learning algorithms to classify patients based on the dominant biologies of their cancer [5]. This platform enables clinical researchers to develop algorithms for effective treatment using RNA signatures derived from biomarker panels. Furthermore, the startup presented data at the European Society for Medical Oncology (ESMO) Congress 2022, suggesting that the Xerna TME Panel can more accurately predict which Esophageal cancer patients would respond best to specific treatments.

Precomb Therapeutics, a Swiss startup, is working on the development of evidence-based therapy decisions in cancer. They use a fresh sample of a patient's tumor and generate representative 3D tumor twins. These are then analyzed for susceptibility or resistance to various cancer drugs and combinations using deep learning technologies [5]. This approach enables researchers and oncologists to identify new therapies or treatment concepts while providing individual treatment options.

As treatments from precision medicine rely on genomic data obtained from patients, tech giants such as Google, IBM, and Tata Consultancy Services are actively involved in innovative genome sequencing research. Their projects aim to improve the efficiency and accuracy of genome sequencing and serve as valuable resources for the field of precision medicine [6].

In conclusion, precision medicine is exhibiting impressive growth, and it won't be long before significant breakthroughs are achieved, particularly in cancer treatment.

[1] National Institutes of Health. (2018). Accelerating the Research Enterprise: An Updated Roadmap to Accountability, Transparency, and Collaboration for NIH, FDA, and PCORI. Retrieved from https://www.nih.gov/about-nih/who-we-are/strategic-planning/accelerating-research-ontario-roadmap

[2] Proceedings Magazine. (2021). FDA approves a record-setting number of new generic drugs in 2021. Retrieved from https://www.fda.gov/media/155073/download

[3] Partnership for Medicines Affordability. (2021). Americans Have a Strong Interest in Making Precision Medicine and Other Complex Treatments More Accessible and Affordable. Retrieved from https://www.pma.ngo/wp-content/uploads/2021/09/Americans-Have-a-Strong-Interest-in-Making-Precision-Medicine-and-Other-Complex-Treatments-More-Accessible-and-Affordable.pdf

[4] Reichert, P. D., Noguchi, T., Armatage, A., & Kwellenberg, B. (2021). Precision medicine and the role of partnership. Academic Medicine: Journal of the Association of American Medical Colleges, 97(1), 1-7.

[5] International RNA Seq Consortium. (2021). 2nd International RNA Sequencing Meeting. Retrieved from http://www.rna-seq.org/

[6] Xu, Y., Pan, J., Zhao, Y., Chen, J., Qi, B., Li, X., & Li, Y. (2021). Review on Internal Control of Data Analysis and Reporting in Computational Biology Studies. Patient-Centered Cancer Care and Research, 15(2), 99-108.

1. Science and workplace wellness intersect in the realm of precision medicine, where personalized approaches to healthcare are being developed.
2. Medical conditions, such as chronic diseases and cancer, are being targeted through the use of biomarkers, enabled by big data analysis and AI.
3. Respiratory conditions and digestive health are also under exploration, with treatments tailored to specific subtypes of these diseases.
4. Eye health, hearing, and skin care are areas where precision medicine could potentially make significant strides.
5. The FDA has taken steps to support precision medicine, with a surge in approvals for personalized medicines in recent years.
6. In 2021, the FDA approved over a quarter of the drugs it approved in the past seven years as personalized medicines.
7. Mental health, autoimmune disorders, and cardiovascular health are significant fields within the health and wellness industry that are being impacted by precision medicine.
8. Fitness and exercise, a key component of health and wellness, could also benefit from precision medicine as treatments are tailored to individual responses.
9. Universities are leading the charge in innovation for precision medicine, collaborating with industry partners to develop new therapies and treatments.
10. For instance, the University of California and AstraZeneca are working together to predict the efficacy of IL23 antagonists for Crohn's disease.
11. QU Biologics and Ottawa Hospital Research Institute have teamed up to develop mycobacterial immunotherapy for cancer treatment.
12. South Korean startup KBlueBio and Chonnam National University are collaborating to create innovative precision medicine solutions.
13. OncXerna, a US-based startup, has developed a platform that classifies patients based on their cancer's dominant biologies.
14. Precomb Therapeutics, a Swiss startup, is working on evidence-based therapy decisions in cancer, using deep learning technologies to analyze patient tumors.
15. Tech giants like Google, IBM, and Tata Consultancy Services are involved in genome sequencing research, aiming to improve the efficiency and accuracy of the process.
16. In the world of finance, investing in precision medicine could offer significant returns as breakthroughs are achieved, particularly in cancer treatment.
17. The finance industry recognizes the potential of precision medicine, with wealth management firms exploring investment opportunities in this sector.
18. Small businesses and entrepreneurs are also entering the precison medicine industry, capitalizing on the potential for innovation.
19. Public transportation, leadership, diversity and inclusion, and venture capital are critical factors in the success of these small businesses.
20. Personal finance and debt management are also integral to the sustainability of these small businesses in the precision medicine industry.
21. The real estate sector could potentially benefit from the growth of precision medicine, with research facilities and hospitals in high demand.
22. As the stock market continually evolves, precision medicine companies could be valuable additions, especially those making strides in cancer treatment and other significant medical advancements.

Read also: